shares of Autolus Therapeutics PLC (AUTL) on
Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company’s clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.